The phase III clinical trial of albumin-bound paclitaxel nanoparticles in combination with an anti-programmed death-ligand 1 (PD-L1) antibody for the treatment of metastatic triple-negative breast cancer has notably extended the survival period of patients with favorable safety profiles [466]. Here, ALB is linked to triple-negative breast carcinoma.